



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/033,770	12/27/2001	Shuang Liu	PH-7124	9015

23914 7590 06/05/2003

STEPHEN B. DAVIS
BRISTOL-MYERS SQUIBB COMPANY
PATENT DEPARTMENT
P O BOX 4000
PRINCETON, NJ 08543-4000

EXAMINER

SHARAREH, SHAHNAM J

ART UNIT	PAPER NUMBER
----------	--------------

1617

DATE MAILED: 06/05/2003

3

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/033,770

Applicant(s)

LIU, SHUANG

Examiner

Shahnam Sharareh

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 December 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-60 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-60 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: |

El ction/Restrictions

Claims 1-60 are subject to various permutations of compounds so that the following patentably distinct subgenus groups have been identified. Accordingly, Restriction to one of the following inventions is required under 35 U.S.C. § 121:

1. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is CR_3 , X is $(CR_9R_{10})_m$, classified in class 585, subclass 1+
2. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is CR_3 , X is NR_{11} , Classified in class 564, subclass 1+,
3. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is CR_3 , X is $O(CR_9R_{10})_m$, class 568, subclass 256+
4. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is N, X is $(CR_9R_{10})_m$, class 564, subclass 200+
5. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is N, X is NR_{11} , Class 564, subclass 1.5+
6. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is N, X is $O(CR_9R_{10})_m$, class 568, subclass 3+
7. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P, X is $(CR_9R_{10})_m$, class 568, subclass 8+
8. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P, X is NR_{11} , class 510, subclass 467+
9. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P, X is $O(CR_9R_{10})_m$, in class 568, subclass 10+

Art Unit: 1617

10. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P=O, X is $(CR_9R_{10})_m$, in class 562 subclass 4+
11. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P=O, X is NR_{11} , in class 562 subclass 4+
12. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P=O, X is $O(CR_9R_{10})_m$, in class 562 subclass 4+
13. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P=S, X is $(CR_9R_{10})_m$, in class 568 subclass 8+
14. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P=S, X is NR_{11} , in class 568 subclass 8+
15. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is P=S, X is $O(CR_9R_{10})_m$, in class 562 subclass 8+
16. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is As, X is $(CR_9R_{10})_m$, in class 556, subclass 30+
17. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is As, X is NR_{11} , in class 556 subclass 30+
18. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is As, X is $O(CR_9R_{10})_m$, in class 562 subclass 30+
19. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds compositions wherein A is As=O, X is $O(CR_9R_{10})_m$, in class 562, subclass 45+
20. Claims 1-7 in part, 26, 43, 45-46 drawn to compounds and compositions wherein A is As=O, X is NR_{11} , in class 562, subclass 45+

Art Unit: 1617

21. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $\text{As}=\text{O}$, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, in class 562, subclass 45+
22. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $-\text{[C(L)R}_{12}(\text{Cr}_{13}\text{R}_{14})\text{a]b-}$, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, in class 585, subclass 1+
23. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $[\text{C(L)R}_{12}(\text{Cr}_{13}\text{R}_{14})\text{a]b-}$, X is NR_{11} , in class 585, subclass 1+
24. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $-\text{[C(L)R}_{12}(\text{Cr}_{13}\text{R}_{14})\text{a]b-}$, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, in class 581, subclass 1+
25. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $-\text{[N(L)C(W)(CR}_{15}\text{R}_{16})\text{c]d-}$, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, in class 534, subclass 1+
26. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $-\text{[N(L)C(W)(CR}_{15}\text{R}_{16})\text{c]d-}$, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, in class 534, subclass
1+
27. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $-\text{[N(L)C(W)(CR}_{15}\text{R}_{16})\text{c]d-}$, X is NR_{11} , in class 534, subclass 1+
28. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $-\text{[NR}_{20}\text{C(W)C(L)R}_{21}(\text{CR}_{22}\text{R}_{23})\text{g]h[NR}_{24}\text{C(W)(CR}_{25}\text{R}_{16})\text{I]j-}$
 $(\text{L)R}_{12}(\text{Cr}_{13}\text{R}_{14})\text{a]b-}$, X is $(\text{CR}_9\text{R}_{10})_m$, in class 534, subclass 1+
29. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein
A is $-\text{[NR}_{20}\text{C(W)C(L)R}_{21}(\text{CR}_{22}\text{R}_{23})\text{g]h[NR}_{24}\text{C(W)(CR}_{25}\text{R}_{16})\text{I]j-}$
 $(\text{L)R}_{12}(\text{Cr}_{13}\text{R}_{14})\text{a]b-}$, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$ in class 534, subclass 1+

Art Unit: 1617

30. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein A is $-\{[NR_{20}C(W)C(L)R_{21}(CR_{22}R_{23})g]h[NR_{24}C(W)(CR_{25}R_{16})l]j\}-(L)R_{12}(Cr_{13}R_{14})a]b-$, X is NR_{11} , in class 534, subclass 1+
31. Claims 1-7 in part, 26, 43 drawn to compounds and compositions wherein A is $-\{[NR_{20}C(W)C(L)R_{21}(CR_{22}R_{23})g]h[NR_{24}C(W)(CR_{25}R_{16})l]j\}-(L)R_{12}(Cr_{13}R_{14})a]b-$, X is NR_{11} , in class 534, subclass 1+
32. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is CR_3 , X is $(CR_9R_{10})_m$, class 424, subclass 1.37+, and in their respective tripodal compound class
33. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is CR_3 , X is NR_{11} , Class 424, subclass 1. +, or class 534, subclass 10+ and in their respective tripodal compound class
34. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is CR_3 , X is $O(CR_9R_{10})_m$, class 424, subclass 1.38, +, or class 534, subclass 10+ and in their respective tripodal compound class
- Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is N, X is $(CR_9R_{10})_m$, class 424, subclass 1.37+, or class 534, subclass 10+ and in their respective tripodal compound class

Art Unit: 1617

35. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is N, X is NR_{11} , Class 424, subclass 1.37 +, or class 534, subclass 10+ and in their respective tripodal compound class
36. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is N, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, class 424, subclass 1.38 +, or class 534, subclass 10+ and in their respective tripodal compound class
37. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is CR_3 , X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, class 424, subclass 1.38 +, or class 534, subclass 10+ and in their respective tripodal compound class
38. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is $\text{P}=\text{O}$, X is $(\text{CR}_9\text{R}_{10})_m$, class 424, subclass 1.37+, or class 534, subclass 10+ and in their respective tripodal compound class
39. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is $\text{P}=\text{O}$, X is NR_{11} , Class 424, subclass 1.37 +, or class 534, subclass 10+ and in their respective tripodal compound class
40. Claims 8-13, 32, 47-48, 53, 59-60 in part, drawn to radiopharmaceutical compounds containing a radionuclei and a tripodal compound wherein A is

Art Unit: 1617

$P=O$, X is $O(CR_9R_{10})_m$, class 424, subclass 1.38+, or class 534, subclass 10+ and in their respective tripodal compound class

41. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is CR_3 , X is $(CR_9R_{10})_m$, class 424, subclass 9.3+, and in their respective tripodal compound class
42. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is CR_3 , X is NR_{11} , Class 424, subclass 9.3+, and in their respective tripodal compound class
43. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is CR_3 , X is $O(CR_9R_{10})_m$, class 424, subclass 9.3+, and in their respective tripodal compound class
44. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is N, X is $(CR_9R_{10})_m$, class 424, subclass 9.3+, and in their respective tripodal compound class
45. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is N, X is NR_{11} , Class 424, subclass 9.3 +, and in their respective tripodal compound class

Art Unit: 1617

46. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is N, X is $O(CR_9R_{10})_m$, class 424, subclass 1.38 +, and in their respective tripodal compound class
47. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is CR_3 , X is $O(CR_9R_{10})_m$, class 424, subclass 9.3 +, and in their respective tripodal compound class
48. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A $P=O$, X is $(CR_9R_{10})_m$, class 424, subclass 9.3+ and in their respective tripodal compound class
49. Claims 14-19 in part, 40, 51-52 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is $P=O$, X is NR_{11} , Class 424, subclass 9.3 +, and in their respective tripodal compound class
50. Claims 20-25 in part, 36, 49-50 drawn to MRI compounds containing a paramagnetic metal ion and a tripodal compound wherein A is $P=O$, X is $O(CR_9R_{10})_m$, class 424, subclass 9.3+, and in their respective tripodal compound class
51. Claims 20-25 in part, 36, 49-50 drawn to X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82,

Art Unit: 1617

- 83, 90 and a tripodal compound wherein A is CR_3 , X is $(CR_9R_{10})_m$, class 424, subclass 9.4+, and in their respective tripodal compound class
52. Claims 20-25 in part, 36, 49-50 drawn to X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is CR_3 , X is NR_{11} , Class 424, subclass 9.4+, and in their respective tripodal compound class
53. Claims 20-25 in part, 36, 49-50 drawn X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is CR_3 , X is $O(CR_9R_{10})_m$, class 424, subclass 9.4+, and in their respective tripodal compound class
54. Claims 20-25 in part, 36, 49-50 drawn X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is N, X is $(CR_9R_{10})_m$, class 424, subclass 9.4+, and in their respective tripodal compound class
55. Claims 20-25 in part, 36, 49-50 drawn X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is N, X is NR_{11} , Class 424, subclass 9.4 +, and in their respective tripodal compound class
56. Claims 20-25 in part, 36, 49-50 drawn X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is N, X is $O(CR_9R_{10})_m$, class 424, subclass 9.4+, and in their respective tripodal compound class

Art Unit: 1617

57. Claims 20-25 in part, 36, 49-50 drawn X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is CR_3 , X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, class 424, subclass 9.4 +, and in their respective tripodal compound class
58. Claims 20-25 in part, 36, 49-50 drawn to X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A $\text{P}=\text{O}$, X is $(\text{CR}_9\text{R}_{10})_m$, class 424, subclass 9.4+ and in their respective tripodal compound class
59. Claims 20-25 in part, 36, 49-50 drawn to X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is $\text{P}=\text{O}$, X is NR_{11} , Class 424, subclass 9.4+, and in their respective tripodal compound class
60. Claims 20-25 in part, 36, 49-50 drawn X-ray or CT contrast agents containing a heavy metal ion of atomic number 21-31, 39-50, 56-80, 82, 83, 90 and a tripodal compound wherein A is $\text{P}=\text{O}$, X is $\text{O}(\text{CR}_9\text{R}_{10})_m$, class 424, subclass 9.4+, and in their respective tripodal compound class
61. Claims 27-31 in part, drawn to methods for treating bone disorders, classified in class 424, subclass 1.11+
62. Claims 33-35, in part, drawn to methods of radioactive imaging, classified in class 424, subclass 9.3+
63. Claims 37-39, in part, drawn to methods of MRI imaging, classified in class 424, subclass 9.35+.

Art Unit: 1617

- 64. Claims 44 in part, drawn to methods of performing X-ray classified in class 424, subclass 9.4+
- 65. Claims 54-58 in part, drawn to compositions and methods of use thereof classified in class 424, subclass 1.11+

The inventions are distinct, each from the other because of the following reasons:

All Inventions drawn to method of use, inventions 61-65, and their respective inventions directed to compounds; inventions 1-60, are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, all methodologies may be practiced with other patentably distinct product conventionally used in the art.

The instant compound and composition claims; claims 1-60, are directed to Markush-type generic claims, which include a plurality of alternatively usable members, directed to independent and distinct invention. It is well settled patent law that a Markush group must contain an immutable structural core responsible for the claimed activity. Applicant fails to provide an immutable central core structure for the proffered claims thereby presenting an improper Markush group for examination. Failure to link the claimed compounds with an immutable core structure results in claims reading on more than one invention, requiring restriction under 35 USC 121.

Art Unit: 1617

In the instant case, inventions 1-60 are related as mutually exclusive species. Accordingly, the members within the instant claims are so unrelated and diverse that a prior art reference anticipating the claim with respect to one of the members would not render the claims obvious under 35 USC 103 with respect to the other member(s).

Further, there is no identifiable "fundamental common core structure" that can be attributed to a biological activity. In fact, variation at A and X modifies the nature of the compound and the scope of search. Each of the above subgenus has a different classification. Accordingly, the generic compound of claim 1 is restricted to patentably distinct subgenus as set forth above.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and the search required for one Group is not required for the other, restriction for examination purposes as indicated is proper.

Claims 1-60 are also generic to a plurality of disclosed patentably distinct species comprising R₁₋₂₆, (set forth in claims 1-60) and various polyaminophosphonate chelants. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over

Art Unit: 1617

the prior art, the evidence or admission may be used in a rejection under 35

U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined and a listing of all claims readable thereon, including any claims subsequently added, even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

This requirement is set in written form, as the restriction is complex (MPEP 812.01). Nevertheless, a telephone call was made to Rodney Burton on June 3, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.


Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shahnam Sharareh whose telephone number is 703-306-5400. The examiner can normally be reached on 8:30 am - 6:00 pm.

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, PhD can be reached on 703-308-1877. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1123.

A handwritten signature in black ink, appearing to be 'Shahnam Sharareh', written in a cursive style.

Shahnam Sharareh
Patent Examiner, AU 1617